Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

556
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
556
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.4K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.

JCO precision oncology·2026
Same author

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Lancet regional health. Americas·2026
Same author

Clinicopathologic Study of 39 Mismatch Repair-deficient Sarcomas Demonstrates Recurrent Histologic Patterns and Supports Universal Screening of Pleomorphic Rhabdomyosarcoma, Uterine Leiomyosarcoma, and Undifferentiated and Unclassified Sarcomas.

The American journal of surgical pathology·2026
Same author

Exercise in MPNs: a promising first step.

Blood advances·2026
Same author

Echocardiographic high-output heart failure is associated with worse survival among patients with myelofibrosis.

Cardio-oncology (London, England)·2026
Same author

Ruxolitinib and heart failure outcomes among patients with myelofibrosis.

Leukemia & lymphoma·2026

Related Experiment Video

Updated: Oct 10, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K

Blast and accelerated phase CML: room for improvement.

Joan How1,2,3, Vinayak Venkataraman1, Gabriela Soriano Hobbs1

  • 1Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Hematology. American Society of Hematology. Education Program
|December 10, 2021
PubMed
Summary
This summary is machine-generated.

Tyrosine kinase inhibitors (TKIs) have greatly reduced progression in chronic myeloid leukemia (CML). However, advanced CML phases still require novel strategies for lasting remission.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

327
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.8K

Related Experiment Videos

Last Updated: Oct 10, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

327
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.8K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) treatment, significantly decreasing progression to advanced phases.
  • Despite TKI advancements, accelerated phase (AP) and blast phase (BP) CML remain challenging, with poorer outcomes compared to chronic phase CML.

Observation:

  • AP- and BP-CML affect a small patient subset, but their prognosis is considerably worse, showing reduced response rates and duration to TKI therapy.
  • TKIs have improved outcomes in advanced CML, especially for de novo AP, yet often fail to achieve durable remissions.

Findings:

  • Achieving a second chronic phase is the primary therapeutic goal in advanced CML, often necessitating induction chemotherapy combined with TKIs.
  • The limited patient population with advanced CML presents challenges for developing novel treatments and investigational agents.

Implications:

  • Clinical trial participation is strongly encouraged for patients with AP and BP CML.
  • Optimal management of advanced CML involves careful TKI selection, combination therapies, consideration of bone marrow transplantation, and exploration of novel agents.